Clinical Trial Detail

NCT ID NCT02489448
Title Neoadjuvant MEDI4736 Concomitant With Weekly Nab-paclitaxel and Dose-dense AC for Stage I-III Triple Negative Breast Cancer
Recruitment Suspended
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Yale University
Indications

triple-receptor negative breast cancer

Therapies

Durvalumab + Nab-paclitaxel

Cyclophosphamide + Doxorubicin

Age Groups: adult

No variant requirements are available.